BAYER AG NA O.N./ DE000BAY0017 /
2024-03-18 9:59:35 PM | Chg. -0.140 | Volume | Bid9:59:36 PM | Ask9:59:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
26.095EUR | -0.53% | 224,949 Turnover: 5.9 mill. |
26.095Bid Size: 500 | 26.150Ask Size: 2,215 | 25.74 bill.EUR | 0.42% | - |
GlobeNewswire
03-18
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M...
GlobeNewswire
03-06
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
03-04
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
02-15
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire
02-13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
02-13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
01-05
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GlobeNewswire
01-04
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...
GlobeNewswire
2023-12-14
Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Su...
GlobeNewswire
2023-12-06
NFWF Announces $4.1 Million in Grants to Conserve the Monarch Butterfly and Other Insect Pollinators